

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## GUIDANCE EXECUTIVE (GE)

**Review of TA261; Rivaroxaban for the treatment and secondary prevention of venous thromboembolism, and TA287; Rivaroxaban for the treatment of acute symptomatic pulmonary embolism with or without symptomatic DVT and the prevention of recurrent VTE**

### Final recommendation post consultation

TA261 and TA287 will be transferred to the 'static guidance' list.

#### **1. Background**

This guidance was issued in July 2012 (TA261) and June 2013 (TA287).

At the GE meeting of 28 April 2015 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

#### **2. Proposal put to consultees and commentators**

TA261 and TA287 should be transferred to the 'static guidance' list.

#### **3. Rationale for selecting this proposal**

No new evidence has been identified that suggests that a review of the guidance is necessary.

#### **4. Summary of consultee and commentator responses**

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p><b>Respondent:</b> Bayer</p> <p><b>Response to proposal:</b> Agree</p> <p>Bayer supports with the proposal to transfer appraisals TA261 and TA287 to the static guidance list.</p>	<p><b>Comment from Technology Appraisals</b></p> <p>Comment noted. No action required.</p>
---	--

**Paper signed off by:** Janet Robertson, 16 June 2015

**Contributors to this paper:**

Technical Lead: Caroline Hall

Project Manager: Andrew Kenyon